New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 9, 2014
08:19 EDTICPTIntercept shares more than double in pre-market after NASH primary endpoint met
Shares of Intercept Pharmaceuticals are up about 140% to $173.00 in pre-market trading after the company announced that the FLINT trial of obeticholic acid, or OCA, for the treatment of nonalcoholic steatohepatitis, or NASH, has been stopped early for efficacy based on a planned interim analysis showing that the primary endpoint of the trial has been met. Intercept closed trading yesterday at $72.39.
News For ICPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 19, 2014
06:26 EDTICPTIntercept price target lowered to $475 from $693 at Citigroup
Citigroup lowered its price target for Intercept shares to $475 on expectations investor concerns around the company's liver fibrosis drug, OCA, will persist. Citi, however, says it remains a buyer of the stock. It believes the level of concern around OCA’s cholesterol effect is overdone. The firm keeps a Buy rating on shares of Intercept.
December 18, 2014
06:33 EDTICPTIntercept coverage resumed with a Buy at Sterne Agee
Subscribe for More Information
December 15, 2014
08:58 EDTICPTIntercept reinstated with a Buy at BofA/Merrill
Subscribe for More Information
December 11, 2014
08:57 EDTICPTLeerink major pharma & biotech analysts hold analyst/industry conference call
Subscribe for More Information
December 5, 2014
06:06 EDTICPTIntercept announces publication of meta-analysis from Global PBC Study Group
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use